At ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) discussed VHL-associated renal cell carcinoma (RCC) and the latest Belzutifan data. The LightSpark 015 study, presented for the first time in China, showed an 83% ORR in RCC patients, reinforcing the potential of HIF-2α inhibitors as a breakthrough therapy.
